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The hallmark of type 2 diabetes is excessive he-
patic glucose production. Several transcription
factors and coactivators regulate this process
in cultured cells. But gene ablation experiments
have yielded fewclues as to the physiologicme-
diators of this process in vivo. We show that
inactivation of the gene encoding forkhead pro-
tein Foxo1 in mouse liver results in 40% reduc-
tion of glucose levels at birth and 30% reduction
in adult mice after a 48 hr fast. Gene expression
and glucose clamp studies demonstrate that
Foxo1 ablation impairs fasting- and cAMP-in-
duced glycogenolysis and gluconeogenesis.
Pgc1a is unable to induce gluconeogenesis in
Foxo1-deficient hepatocytes, while the cAMP
response is significantly blunted. Conversely,
Foxo1 deletion in liver curtails excessive glu-
coseproduction causedbygeneralizedablation
of insulin receptors and prevents neonatal dia-
betes and hepatosteatosis in insulin receptor
knockout mice. The data provide a unifying
mechanism for regulation of hepatic glucose
production by cAMP and insulin.
INTRODUCTION
The mechanism by which hormones regulate hepatic glu-
cose metabolism is a key question in biology with critical
ramifications for pathogenesis and treatment of metabolic
diseases (Matsumoto and Accili, 2006). Hepatic glucose
production (HGP) can be viewed as the product of the op-
posing actions of glucagon, acting through cAMP-depen-
dent pathways, and insulin, acting through the PI 3-kinase
pathway.Acutehormonaleffectsare independentofprotein
synthesis (Exton and Park, 1968; Grempler et al., 2005;208 Cell Metabolism 6, 208–216, September 2007 ª2007 ElsevSasaki et al., 1984) and transcriptional in nature (O’Brien
and Granner, 1996). Ambiguity persists on the identity and
interactions of hormone-regulated factors controlling
transcription of rate-limiting glucogenic enzymes, such as
phosphoenolpyruvate carboxykinase (Pck1) and glucose-6
phosphatase (G6pc) (O’Brien and Granner, 1996).
The Creb-Torc2 pathway is acutely activated by cAMP
to promote HGP in a Pgc1a-dependent manner , but does
not respond to insulin (Koo et al., 2005). The coactivator
Cbp is recruited to Creb when the latter is phosphorylated
(Chrivia et al., 1993). It has been shown that insulin phos-
phorylates Cbp to inhibit gluconeogenesis by disrupting
the Creb/Cbp complex (Zhou et al., 2004). However, the
recent demonstration that Creb is promiscuously phos-
phorylated by both cAMP and insulin (Koo et al., 2005)
makes this explanation problematic. Among transcrip-
tional coactivators, Pgc1a is induced by fasting and is
required for the Creb-Torc2 induction of gluconeogenesis
(Koo et al., 2004). But it is disputed whether Pgc1a is itself
the target of insulin regulation (Herzig et al., 2001) or is
regulated via Foxo1 (Puigserver et al., 2003; Yoon et al.,
2001). And the phenotype of Pgc1a-deficient mice is nota-
ble for the absence of significant abnormalities of glucose
production (Lin et al., 2004).
The forkhead transcription factor Foxo1 confers insulin
responsiveness ontoG6pc expression (Nakae et al., 2001)
by interacting with Pgc1a (Puigserver et al., 2003). None-
theless, its involvement in HGP has been evinced exclu-
sively from gain-of-function or partial loss-of-function
studies (Nakae et al., 2001, 2002; Puigserver et al., 2003;
Samuel et al., 2006), leading to controversy as to whether
it is required for either the Pgc1a (Schilling et al., 2006) or
the insulin response (Herzig et al., 2001; Yeagley et al.,
2001). Although a dominant negative Foxo1, lacking the
transactivation domain, reduces gluconeogenesis (Nakae
et al., 2001) and reverses hyperglycemia in ob/ob mice
(Altomonte et al., 2003), this approach is tainted by poten-
tial off-target effects of the mutant Foxo1. To examine this
question, we ablated Foxo1 expression in mouse hepato-
cytes using cre-loxP mutagenesis.ier Inc.
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Foxo1 and Hepatic Glucose ProductionFigure 1. Generation and Metabolic
Features of l-Foxo1 Mice
(A andB) Expression of Foxo1 (A) and Foxo3 (B)
mRNA in 10-week-old l-Foxo1 (filled bars) and
littermate control mice (open bars). n = 4 for
each genotype.
(C) Western blot analysis of Foxo1 in liver.
(D) Blood glucose levels at postnatal day 2.
(E) PAS staining of liver sections in l-Foxo1 and
littermate controls. One asterisk indicates
p < 0.05, two asterisks indicates p < 0.01.RESULTS
Generation and Analysis of Liver-Specific
Foxo1 Knockouts
To ablate Foxo1 in hepatocytes, we intercrossed mice
homozygous for a floxed Foxo1 allele (Paik et al., 2007)
with a1 antitrypsin-cre mice (henceforth, l-Foxo1 mice).
Hepatic Foxo1 mRNA (Figures 1A and 1B) and protein
(Figure 1C) levels were decreased by 90% in l-Foxo1
mice, compared to controls. In contrast, expression of
the isoform Foxo3a was unchanged (Figure 1B) as was
expression of Foxa2, a related transcription factor that
regulates liver metabolism (Wolfrum et al., 2004; Zhang
et al., 2005) (Figure 1C).
At birth, l-Foxo1 mice showed a 40% decrease of blood
glucose level (Figure 1D), while hepatic glycogen in-
creased (Figure 1E and data not shown). In adult mice,
fasting induced glycogenolytic (G6pc) and gluconeoge-
netic genes (Pck1 and Ppargc1a) 2- to 4-fold. In l-Foxo1
mice, G6pc expression failed to increase with fasting,
while the rise of Pck1 and Ppargc1a was curtailed by
50%,aswasexpression of twoFoxo1 target genes, insu-
lin-like growth factor binding protein-1 (Igfbp1) (Guo et al.,
1999), and insulin receptor substrate 2 (Irs2) (Zhang et al.,
2001) (Figure 2A). In contrast, Foxo1-independent meta-
bolic pathways, such as those mediated by Srebf1c (Hor-
ton et al., 2003) and glucokinase (Gck) (Dentin et al., 2004),
were unaffected (Figure 2A). These data indicate that
deletion of Foxo1 affected only the expression of Foxo1Cell Metarget genes and did not result in widespread hepatotoxic-
ity (Table 1). Consistent with the changes in glucogenetic
gene expression, l-Foxo1 mice showed 30% lower blood
glucose levels comparedwith controlmice after prolonged
(48 hr) fasting (Figure 2B). Notably, 10% of the l-Foxo1
mice developed neuroglycopenia, with seizures that
were relieved by glucose administration.
To evaluate the effects of altered gene expression on
HGP, we conducted pyruvate challenge tests in 16-week-
old mice. Glucose levels were significantly lower in
l-Foxo1 mice in response to pyruvate administration (Fig-
ure 2C). Moreover, adult l-Foxo1 mice (Table 1) showed
reduced glucose excursions during glucose tolerance
tests compared with control mice (Figure 2D), while insulin
tolerance tests were identical in both groups (Figure 2E).
Decreased Hepatic Glucose Production
in l-Foxo1 Mice
In hyperinsulinemic euglycemic clamps, l-Foxo1 mice re-
quired a 30% increase of the glucose infusion rate to
maintain euglycemia, consistent with a state of height-
ened insulin sensitivity (Figure 2F). Despite this, HGP in
l-Foxo1 was > 50% lower than control mice (Figure 2G),
while peripheral glucose uptake was unaffected (Fig-
ure 2H). The combination of increased glucose infusion
and reduced HGP, in the absence of changes in peripheral
glucose uptake, indicates that glucose is primarily incor-
porated into hepatic glycogen. To analyze changes in he-
patic glucose fluxes, we measured glucose cycling,tabolism 6, 208–216, September 2007 ª2007 Elsevier Inc. 209
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Foxo1 and Hepatic Glucose ProductionFigure 2. Metabolic Effects of Hepatic Foxo1 Ablation in Adult Mice
(A) Expression of hepatic genes in fasted and fed 16-week-old l-Foxo1 and littermate control mice (n = 6–9 mice per group).
(B) Blood glucose levels in 48-hr-fasted animals. * = p < 0.001, control versus l-Foxo1 mice.
(C) Pyruvate challenge.
(D and E) Intraperitoneal glucose tolerance (D) in 16-week-old; and insulin tolerance tests (E) in 12-week-old l-Foxo1 and littermate controls (n = 7–10
mice per group).
(F–K) Glucose clamps. Glucose infusion rates (F), glucose production (G), glucose disappearance (H), glucose cycling (I), glycogenolysis (J), and
gluconeogenesis (K) during hyperinsulinemic euglycemic clamps in 10-week-old l-Foxo1 and littermate controls (n = 9mice per group). l, PAS staining
of liver sections and hepatic glycogen content in 14-week-old l-Foxo1 and littermate controls (n = 8 mice per group). All data are presented as
means ± SEM. One asterisk indicates p < 0.05, two asterisks p < 0.01.
(L and M) Measurements of hepatic glycogen content and PAS staining of liver sections.210 Cell Metabolism 6, 208–216, September 2007 ª2007 Elsevier Inc.
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Foxo1 and Hepatic Glucose Productionglycogenolysis, and gluconeogenesis. Glucose cycling,
i.e., the amount of glucose-6-phosphate that is dephos-
phorylated and released without being further metabo-
lized (Vranic, 1992), decreased by >60% in l-Foxo1
mice, consistent with reduced flux through G6pc
(Figure 2I). Glycogenolysis and gluconeogenesis were
both decreased by 50% (Figure 2J and 2K), consistent
with the gene expression data (Figure 2A). Moreover, fast-
ing hepatic glycogen content in l-Foxo1 mice increased 6-
fold (Figure 2L). These results indicate that Foxo1 ablation
in liver suppresses HGP by decreasing both glycogenoly-
sis and gluconeogenesis.
Foxo1 Is Required for Pgc1a-Dependent Induction
of Pck1 and G6pc
Pgc1amediates HGPduring fast (Herzig et al., 2001; Yoon
et al., 2001) in a Torc2-dependent manner (Koo et al.,
2005). It has been disputed (Schilling et al., 2006) whether
Foxo1 is required for the Pgc1a response (Puigserver
et al., 2003). To address this question, we analyzed
Table 1. Metabolic Characteristics of 16-Week-Old
l-Foxo1 Mice
Parameter Control l-Foxo1
Body weight (g) 27.5 ± 0.7 28.0 ± 1.3
Fat mass (g) 2.41 ± 0.28 2.81 ± 0.44
Fat mass/BW (%) 8.68 ± 2.79 10.10 ± 1.39
Lean mass (g) 22.6 ± 0.5 22.6 ± 1.2
Lean mass/BW (%) 82.48 ± 0.90 80.78 ± 1.03
Liver (g) 1.25 ± 0.07 1.24 ± 0.05
Liver/BW (%) 4.28 ± 0.14 4.47 ± 0.11
Fed Glucose (mg/dl) 177 ± 15 161 ± 17
Glucose (mg/dl) 127 ± 9 131 ± 16
Fed Insulin (ng/ml) 1.04 ± 0.10 0.91 ± 0.07
Insulin (ng/ml) 0.45 ± 0.11 0.40 ± 0.07
Triglyceride (mg/dl) 54 ± 5 60 ± 7
Cholesterol (mg/dl) 102 ± 5 115 ± 6
NEFA (mEq/l) 0.59 ± 0.03 0.65 ± 0.07
b-Hydroxybutyrate (mM) 0.69 ± 0.08 0.89 ± 0.17
Fed Liver triglyceride (mg/g) 15.9 ± 1.8 18.6 ± 1.3
Liver triglyceride (mg/g) 66.7 ± 4.7 72.5 ± 4.8
Liver cholesterol (mg/g) 5.8 ± 0.2 5.5 ± 0.2
Fed Liver glycogen (mg/g) 20.86 ± 3.56 16.83 ± 3.50
AST (IU/l) 27 ± 1 28 ± 1
ALT (IU/l) 3 ± 1 3 ± 0.1
g-GTP (IU/l) 9 ± 3 10 ± 1
ALP (IU/l) 23 ± 1 23 ± 1
Albumin (g/dl) 20.9 ± 3.6 16.8 ± 3.5
All data, unless otherwise indicated, were obtained in over-
night-fasted animals. No difference achieved statistical
significance.Cell MetPgc1a’s ability to regulate glucogenic genes in hepato-
cytes lacking Foxo1. In hepatocytes derived from control
mice, transduction of Pgc1a increasedG6pc andPck1 ex-
pression 2,500- and 80-fold, respectively (Figure 3,
empty bars). Insulin partly inhibited Pgc1a-induced gene
expression. In Foxo1-deficient hepatocytes, Pgc1a induc-
tion of either gene decreased by >95% (Figure 3, full bars).
In contrast, Pgc1a induction of Cycs and Atp5b genes,
which are not regulated by Foxo1, was preserved. These
data indicate that Foxo1 is required for Pgc1a induction
of hepatic glucogenetic genes.
We next assessed the effect of Foxo1 inactivation in pri-
mary hepatocytes, using a short-hairpin (sh) RNA adeno-
virus to reduce Foxo1 expression by 90% (Figure 4A).
We examined gene expression induced by cAMP (G6pc),
dexamethasone (Igfbp1), or both (Pck1 and Ppargc1a). In
all instances, Foxo1 ablation reduced the hormonal re-
sponse by 50% to 70% (Figure 4B), indicating that
Foxo1 plays a role in both cAMP and glucocorticoid induc-
tion of hepatic gene expression. Consistent with these
results, Foxo1 shRNA curtailed basal and prevented
cAMP-induced glucose release in themedium (Figure 4C).
Moreover, expression of Foxo1 target genes in the insulin
signaling pathway was also decreased by 50%, with
a commensurate decrease of insulin-induced phosphory-
lation (Figure 4D and 4E) (Gershman et al., 2007; Ide et al.,
2004; Matsumoto et al., 2006; Puig and Tjian, 2005; Zhang
et al., 2001). These changes in gene expression attenu-
ated insulin signaling in hepatocytes expressing Foxo1
shRNA (Figure 4E).
Figure 3. PGC1a-Induced Gluconeogenic and Mitochondrial
OXPHOS Gene Expression in Primary Hepatocyte Cultures
Prepared from l-Foxo1 or Control Mice
After transduction with adenovirus encoding either PGC1a or b-galac-
tosidase, hepatocyte cultures were incubated with or without insulin
(100 nM) in serum-free mediun for 24 hr. The difference between
control and Foxo1 shRNA is statistically significant at all doses tested
(p < 0.001).abolism 6, 208–216, September 2007 ª2007 Elsevier Inc. 211
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Foxo1 and Hepatic Glucose ProductionFigure 4. Effects of Loss of Function of Foxo1 on Glucose Production in Primary Hepatocytes
(A) Decrease of Foxo1 mRNA (lower panel) and protein (immunoblot) levels following Foxo1 shRNA transduction.
(B) Induction of G6pc, Pck1, Ppargc1a, and Igfbp1 by cAMP and/or dexamethasone and inhibition by insulin in Foxo1 knockdown hepatocytes (C:
control shRNA adenovirus; F: Foxo1 shRNA adenovirus). The difference between control and Foxo1 shRNA is statistically significant at all doses
tested (p < 0.01).
(C) Reduction of glucose release into the medium in Foxo1 knockdown hepatocytes.
(D) Levels of insulin receptor (Insr), Irs1, and Irs2 mRNA.
(E) Tyrosine phosphorylation and protrein amounts of Insr, Irs1, and Irs2, and association of Pi 3-kinase p85 subunit with Irs1 and Irs2. Hepatocytes
were treated with insulin, and subjected to immunoprecipitation (IP) and immunoblot (IB) with the indicated antibodies.
(F) Induction of G6pc, Pck1, and Ppargc1a by cAMP and inhibition by insulin in Foxo1 knockout hepatocytes. (G) Reduction of glucose release in
Foxo1 knockout hepatocytes. One asterisk indicates p < 0.01.WealsostudiedthecAMPresponse inprimaryhepatocytes
from l-Foxo1mice.Weobserved a 50%decrease inG6pc in-
duction and a 30%decrease inPpargc1a induction, whereas
Pck1 expression was unaffected (Figure 4F). Glucose release212 Cell Metabolism 6, 208–216, September 2007 ª2007 Elsevin the medium decreased by 25% (Figure 4G). The differ-
ence between the knockdown and knockout hepatocytes
indicates that adaptive mechanisms (e.g., Foxo3) can com-
pensate for chronic, but not for acute, Foxo1 ablation.ier Inc.
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Foxo1 and Hepatic Glucose ProductionFigure 5. Hepatic Foxo1 Ablation in Insr/ Mice
(A) Metabolic parameters in WT control, Insr/ and Insr/::l-Foxo1 mice (Dko) (n = 7 mice for each group).
(B) Kaplan-Meier plots of Insr/ (solid line) and Dko mice (dotted line).
(C) Appearance of the liver, PAS, and oil red O staining of liver sections in Insr/ and Dko mice. The liver is outlined for comparison.
(D) Hepatic gene expression in fed mice (n = 6–8 mice for each group). Data in (A)–(D) were obtained at postnatal day 2.
(E) Metabolic parameters in 14-week-old Dko (filled bars) and littermate controls (open bars) (n = 7 mice for each group). Data are means ± SEM.
(F) Necroscopic analyses of 14-week-old Dko and control mice.
(G) H&E staining of pancreatic sections demonstrating islet hyperplasia.
(H) PAS and oil red O staining of liver sections.Cell Metabolism 6, 208–216, September 2007 ª2007 Elsevier Inc. 213
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Foxo1 and Hepatic Glucose ProductionGenetic Epistasis of Foxo1 and Insulin Receptor
In diabetes, fasting hyperglycemia reflects an altered
balance between the insulin and glucagon effects on HGP
(Cherrington, 1999). Foxo1 gain-of-function, dominant
negative inhibition, and generalized haploinsufficiency
(Nakae et al., 2001, 2002) have shown impairment and
potentiation, respectively, of insulin action on HGP. But
these results are neither unique to Foxo1 (Hall et al.,
2000; Inoue et al., 2004; Zhang et al., 2005) nor conclusive
that Foxo1 is the physiologic mediator of insulin signaling
to HGP (Schilling et al., 2006; Yeagley et al., 2001). We
tested Foxo1’s role in genetic epistasis experiments. In
C.elegans, Daf16 (Foxo) ablation reverses the dauer phe-
notype of Daf2 (Insr) mutants (Lin et al., 1997; Ogg et al.,
1997). We hypothesized that, if Foxo1 is indeed in the ge-
netic pathway of insulin action, lack of Foxo1 should re-
verse the abnormalities induced by lack of Insr. To test
the hypothesis, we intercrossed insulin receptor-deficient
(Insr/) and l-Foxo1 mice to obtain double knockouts
(Dko) lacking Insr in all tissues and Foxo1 in liver. Insr/
mice develop lethal neonatal diabetic ketoacidosis and
steatosis (Figures 5A–5C) (Accili et al., 1996), independent
of their genetic background (Okamoto et al., 2004). In Dko
mice, metabolic abnormalities were reversed and survival
extended (Figures 5A–5C). Expression of insulin- and
cAMP-regulated genes (G6pc, Pck1, Ppargc1a, Igfbp1,
and Irs2) decreased, while Gck expression increased
(Figure 5D) (Zhang et al., 2006). Approximately 5% of
Dko mice survived to adulthood and, at 14 weeks of
age, they developed severe diabetes with growth retarda-
tion, hepatomegaly, extreme insulin resistance, hyperke-
tonemia, and dyslipidemia (Figure 5E). Histological analy-
ses indicated lipoatrophy specifically in white adipose
tissue (Figure 5F) and b cell hyperplasia (Figure 5G). Dko
mice phenocopy Insr transgenic knockout mice with re-
stored Insr expression in liver (Okamoto et al., 2004), indi-
cating that Foxo1 is the primarymediator of hepatic insulin
signaling. The absence of steatosis in Dko mice raises the
possibility that Foxo1 controls hepatic lipid synthesis
(Matsumoto et al., 2006), in addition to HPG.
DISCUSSION
Our results provide the hitherto missing, critical test of the
hypothesis that Foxo1 is required for hormonal regulation
of HGP. We now show that hepatic Foxo1 ablation results
in the following: (1) 40%reductionof glucose levels at birth,
when glucogenetic genes are first induced (Girard et al.,
1992); (2) 30% reduction of glucose levels in adult mice
after prolonged (48 hr) fasting; (3) fasting-induced neuro-
glycopenia in 10% of l-Foxo1 mice; (4) blunted induction
of glucogenetic genes with fasting; and (5) 50% decrease
of glycogenolysis and gluconeogenesis during hyperinsu-
linemic euglycemic clamps. The data show a surprising
role for Foxo1 as the shared element coordinating HGP
control by cAMP and insulin. Although we have previously
shown that Foxo1 plays a role in insulin inhibition of cAMP-
induced glucose production (Nakae et al., 2001; Puig-214 Cell Metabolism 6, 208–216, September 2007 ª2007 Elsserver et al., 2003), the present data show that it is required
for cAMP induction ofHGP, thus expanding its role. Finally,
the reversal of themetabolic abnormalities of Insr-deficient
mice by hepatic Foxo1 ablation, which virtually phenocop-
ies transgenic restoration of insulin signaling in liver (Oka-
moto et al., 2004), underscores the comprehensive role
of Foxo1 in insulin signaling.
The important role of Foxo1 in HGP can explain the ef-
fects observed in vivo following genetic ablation of other
transcription factors and coregulators that participate in
this process (Matsumoto and Accili, 2006). For example,
despite the well-established role of Pgc1a in the fasting
response, ablation of Pgc1a does not affect gluconeogen-
esis in vivo (Lin et al., 2004). This phenotype has been
ascribed to the compensatory increase of c/Ebpb. But,
based on the present data, it is likelier to result from pre-
served Foxo1 function in Pgc1a-deficient hepatocytes.
HGP is a complex process and is regulated both directly
and indirectly (Obici et al., 2002) via transcriptional and
posttranscriptional mechanism, in response to hormones,
nutrients, and other cues. Because of these complexities
and attendant compensatory mechanisms, it is difficult to
determine the relative contribution of individual transcrip-
tion factors to this process in vivo. In this regard, residual
HGP in Foxo1-deficient liver likely reflects the contribution
of Foxo3 to this process, or thatmediatedbyc/Ebpa (Wang
et al., 1995), NR4 (Pei et al., 2006), STAT3 (Inoue et al.,
2004), Fxr (Ma et al., 2006), and Foxa2 (Zhang et al., 2005).
The selective and limited effect on HGP, brought about
by Foxo1 loss of function in otherwise healthy animals,
supports therapeutic modalities for diabetes treatment,
based on Foxo1 inhibition. In this regard, we should also
point to the increase inGck levels inDkomiceasapotential
added therapeutic benefit of inhibiting Foxo1 in insulin-re-
sistant states. Finally, the absence of tumor-promoting ef-
fects in Foxo1 knockouts (Paik et al., 2007; Tothova et al.,
2007) allays concerns regarding potential, long-term, ad-
verse effects of this approach (Accili and Arden, 2004).
EXPERIMENTAL PROCEDURES
Mice
We generated l-Foxo1 mice using Foxo1flox/flox mice (Paik et al., 2007)
and a1-antitrypsin-cre transgenic mice. The latter were generated us-
ing a construct in which a NLS-containing cre is driven by the 1.2 kb
liver-specific a1-antitrypsin promoter (Shen et al., 1989). We used
ROSA26-eGFP reporter mice to assess specificity of transgene ex-
pression. The line employed herein yielded recombination in liver only
and was already fully active at P0. Insr/ mice have been described
(Accili et al., 1996). The Columbia University Institutional Animal Care
and Utilization Committee approved all experiments.
Chemicals and Antibodies
Insulin, pCPT-cAMP, and dexamethasone are from Sigma; phospho-
Ser473Akt and Akt antibodies are from Cell Signaling; Foxo1 (H-128)
and insulin receptor polyclonal (C-19) and monoclonal (29B4) anti-
bodies are from Santa Cruz Biotechnology; Irs1, Irs2, p85, and phos-
photyrosine (4G10 and PY20) antibodies are from Upstate Biotechnol-
ogy and BD Biosciences, respectively; and actin antibodies (JLA20)
are from Calbiochem. The anti-Foxa2 antiserum has been described
(Sasaki and Hogan, 1994).evier Inc.
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We measured blood or plasma glucose using a glucose monitor (One
Touch Ultra, Lifescan) or glucose oxidase reagent (Teco diagnostics);
insulin levels were measured by ELISA (Mercodia), plasma b-hydroxy-
butyrate, triglyceride (Pointe scientific), cholesterol, and nonesterified
fatty acids by colorimetric assays (Cholesterol E and NEFA C, Wako
Pure Chemicals). Body composition, insulin, glucose tolerance tests
(Nakae et al., 2002), pyruvate tests (Miyake et al., 2002), and hepatic
glycogen measurements have been described (Nakae et al., 2002).
We extracted hepatic triglycerides and cholesterol using 2-propanol
and chloroform/methanol, respectively, and determined levels by
colorimetric assay as described above.
Histological Analyses
We fixed livers and pancreas in 10% formaldehyde for HE and PAS
staining. We used frozen livers for oil red O staining to evaluate hepatic
lipid content.
Hyperinsulinemic Euglycemic Clamp
Studies were performed in conscious, unrestrained, catheterized mice
for 90 min as previously described (Pocai et al., 2005).
RNA and Protein Analysis
We used standard RNA extraction and quantitation procedures
(Matsumoto et al., 2006). Primer sequences are available on request.
Immunoprecipitation and western blotting have been described
(Matsumoto et al., 2006). We prepared hepatic nuclear extracts using
CelLytic NuCLEAR Extraction Kit (Sigma).
Cell Culture
Primary mouse hepatocytes were isolated from 8- to 12-week-old
male mice as described previously (Matsumoto et al., 2002). Cells
were incubated in serum-free Medium 199 overnight before addition
of hormones.
Adenovirus Infection
Adenoviruses encoding PGC1a, control shRNA, or Foxo1 shRNA
have been described (Matsumoto et al., 2006; Puigserver et al.,
2003). Primary hepatocytes were transduced 2 days after plating.
RNA and protein isolation or glucose production were carried out
2 days after transduction. pCPT-cAMP, dexamethasone, and insulin
were added for 6 hr. To analyze protein phosphorylation, we treated
cells with insulin (10 nM) for 2 min.
Glucose Production Assay
We cultured primary hepatocytes in Medium 199 supplemented with
5% FBS or 0.5 mM pCPT-cAMP and measured glucose production
in glucose- and phenol red-free DMEM (pH 7.4) supplemented with
sodium lactate and pyruvate using a colorimetric assay (Invitrogen)
(Yoon et al., 2001).
Statistical Analysis
All results are presented as mean ± SEM. P value was calculated by
unpaired Student’s or Welch’s t tests, as appropriate.
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